C12N 2710/24134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/24134 (Use of virus or viral component as vaccine) appears on 182 US grants and 272 published applications in this corpus.
Search patents in C12N- Granted patents
- 182
- Published applications
- 272
- Assignees
- 129
- Inventors
- 463
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 2 |
| 2004 | 1 | 4 |
| 2005 | 2 | 6 |
| 2006 | 5 | 8 |
| 2007 | 1 | 9 |
| 2008 | 2 | 6 |
| 2009 | 5 | 9 |
| 2010 | 7 | 16 |
| 2011 | 13 | 17 |
| 2012 | 13 | 9 |
| 2013 | 11 | 12 |
| 2014 | 7 | 11 |
| 2015 | 8 | 14 |
| 2016 | 10 | 15 |
| 2017 | 8 | 18 |
| 2018 | 15 | 12 |
| 2019 | 6 | 12 |
| 2020 | 9 | 14 |
| 2021 | 8 | 17 |
| 2022 | 13 | 9 |
| 2023 | 6 | 19 |
| 2024 | 7 | 11 |
| 2025 | 12 | 7 |
| 2026 | 5 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Smallpox vaccine for cancer treatment26 May 2026US 12,636,361 B2Calidi Biotherapeutics (Nevada), Inc.
- Targeted antigen delivery system and uses thereof26 May 2026US 12,636,378 B2SRI International
- Synthetic chimeric vaccinia virus20 Jan 2026US 12,529,036 B2Tonix Pharma Limited
- HBV vaccine13 Jan 2026US 12,521,431 B2Oxford University Innovation Limited
- Immuno-oncolytic therapies6 Jan 2026US 12,514,888 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
- Multi-antigen chimeric vaccine against poxvirus and use thereof20 Aug 2026US 2026/0240989 A1Institute of Microbiology, Chinese Academy of Sciences
- Personalized vaccine13 Aug 2026US 2026/0232778 A1Transgene S. A.
- Recombinant chimeric antigen for poxvirus, subunit vaccine comprising same and use thereof6 Aug 2026US 2026/0226110 A1Beihang University
- Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox18 Jun 2026US 2026/0166138 A1Yale University
Most cited
By later US patents
- Microorganisms for therapy104US 7,588,767 B2Genelux Corporation · 2009
- Microorganisms for therapy98US 7,754,221 B2Genelux Corporation · 2010
- Microorganisms for therapy85US 7,588,771 B2Genelux Corporation · 2009
- Microorganisms for therapy77US 7,662,398 B2Genelux Corporation · 2010
- Compositions and methods to enhance the immune system75US 9,352,037 B2Stichting Sanquin Bloedvoorziening · 2016